Citius Pharmaceuticals logo
Citius Pharmaceuticals CTXR
$ 0.68 -0.98%

Quarterly report 2025-Q4
added 02-13-2026

report update icon

Citius Pharmaceuticals Cash Flow 2011-2026 | CTXR

Annual Cash Flow Citius Pharmaceuticals

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-28.2 M -29.1 M -28.4 M -24.3 M -16.9 M -12.4 M -11.3 M -7.97 M -5.9 M -2.39 M -183 K -1.1 M -918 K -20.8 K

Depreciation & Amortization

1.43 K 2.67 K 2.92 K 1.49 K 844 893 1.75 K 2.63 K 1.34 K - - - - -

Accounts Payables

4.93 M 2.93 M 1.17 M 1.28 M 1.86 M 2.71 M 1.57 M 602 K 909 K 559 K 106 K 11.5 K - 906

All numbers in USD currency

Quarterly Cash Flow Citius Pharmaceuticals

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-13 M - - - -4.73 M - - - -6.14 M - - - -4.82 M -22 M - - -4.65 M -18.7 M -13.8 M - -9.56 M -13.6 M -9.58 M -9.56 M -5.11 M -9.53 M -6.01 M -5.11 M -2.16 M -8.81 M -6.57 M -2.16 M -2.44 M -4.54 M -2.14 M -2.44 M -1.31 M - -4.13 M -1.31 M -697 K -1.68 M -1.05 M -697 K -735 K -603 K -183 K -735 K -522 K -13.2 K -9.97 K -17.5 K -236 -14.9 K -8.9 K -236 -2.2 K -15.8 K -10.7 K -2.2 K

Depreciation & Amortization

- - - - - - - - 578 - - - 730 2.19 K - - 730 761 305 - 153 632 354 153 177 706 470 177 235 1.52 K 1.28 K 235 642 2.02 K 1.34 K 642 672 - 671 672 - - - - - - - - - - - - - - - - - - - -

Accounts Payables

11 M 13.7 M 10.1 M 9.37 M 7.36 M 4.93 M 1.66 M 2.67 M 2.65 M 2.93 M 3.08 M 2.73 M 1.54 M 1.17 M 1.69 M 1.71 M 1.79 M 1.28 M 1.35 M 1.28 M 984 K 1.86 M 1.86 M 1.86 M 1.55 M 2.71 M 2.71 M 2.71 M 2.08 M 1.57 M 1.57 M 1.57 M 561 K 602 K 602 K 602 K 986 K 909 K 909 K 909 K 459 K 559 K 559 K 559 K 199 K 106 K 106 K 106 K 172 K 11.5 K 11.5 K 198 600 - - 906 906 906 906 906

Accounts Receivables

4.05 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

22.6 M 22.3 M 17.2 M 15.3 M 14.4 M 8.27 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Citius Pharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Exelixis Exelixis
EXEL
$ 48.43 9.03 % $ 13.2 B usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.56 3.96 % $ 71.4 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Galapagos NV Galapagos NV
GLPG
$ 28.78 1.36 % $ 2.69 B belgiumBelgium
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Genmab A/S Genmab A/S
GMAB
$ 27.93 1.41 % $ 17.2 B danmarkDanmark
Genprex Genprex
GNPX
$ 0.9 2.02 % $ 839 K usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.41 1.69 % $ 6.83 B spainSpain
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 2.47 25.39 % $ 152 M germanyGermany
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
$ 76.96 2.27 % $ 12.3 B usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.3 1.1 % $ 260 M israelIsrael
BioNTech SE BioNTech SE
BNTX
$ 95.07 -0.45 % $ 27.2 B germanyGermany
Kymera Therapeutics Kymera Therapeutics
KYMR
$ 86.14 4.15 % $ 7.28 B usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 229.83 -1.06 % $ 4.2 B usaUSA
INmune Bio INmune Bio
INMB
$ 1.52 -1.3 % $ 37.6 M usaUSA
Liquidia Corporation Liquidia Corporation
LQDA
$ 41.84 4.26 % $ 3.6 B usaUSA
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 107.42 1.52 % $ 5.39 B usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.32 -0.13 % $ 3.7 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
$ 3.68 28.5 % $ 1.12 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 42.28 21.6 % $ 286 B franceFrance
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.13 0.55 % $ 651 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.47 -8.44 % $ 5.71 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.86 1.88 % $ 3.04 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Puma Biotechnology Puma Biotechnology
PBYI
$ 7.5 2.04 % $ 375 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA